United States Drugs for Gram-Positive Bacterial Infections Industry 2015 ...
The Drugs for Gram-Positive Bacterial Infections market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as ...
Medgadget.com (blog) - Sat, 06 Feb 2016 21:01

Global Drugs for Gram-Positive Bacterial Infections Market 2016 :Industry News ...
QY-Market-Research-300-250248 The market report, titled Drugs for Gram-Positive Bacterial Infections Market 2016, is an analytical research done by Market Research Store study based on the Drugs for Gram-Positive Bacterial Infections market, which ...
Medgadget.com (blog) - Fri, 22 Jan 2016 06:09



Cerus (CERS) Announces Agreement with American Red Cross for Use of INTERCEPT ...
... for the INTERCEPT Blood System for platelets and plasma, which inactivates a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes and is intended to reduce the risk of transfusion-transmitted ...
StreetInsider.com - Tue, 09 Feb 2016 05:30

Cerus Corporation (CERS) Stock Jumps Nearly 10% on American Red Cross Purchase ...
Independent Reporter - Tue, 09 Feb 2016 05:52



Oestrogen promotes healing in a bacterial LPS model of delayed cutaneous wound ...
Collectively, these studies validate K. pneumoniae-derived LPS treatment as a simple yet effective model of bacterial wound infection, while providing the first indication that oestrogen could promote cutaneous healing in the presence of infection ...
Nature.com - Mon, 08 Feb 2016 05:41

News Buzz: Tyson Foods, Inc. (NYSE:TSN), Yelp Inc. (NYSE:YELP), Pathfinder ...
VIBATIV is a bactericidal, once-daily antibiotic with in vitro potency and a dual mechanism of action against Gram-positive bacteria, including difficult-to-treat pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The drug is ...
Stock Transcript - Tue, 09 Feb 2016 06:03



Insect growth regulator wears a second hat: Infection fighter
In a series of tests designed to identify the biological effects, the researchers found that the flies were unusually susceptible to gram-positive bacteria, the kind of germs that cause staph and strep infections, various pneumonias, and anthrax. They ...
Phys.Org - Thu, 28 Jan 2016 09:00

Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 ...
... that it will be submitting a Special Protocol Assessment (SPA) request for phase 3 clinical research of its novel single-dose antibiotic, Brilacidin, for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram ...
SYS-CON Media (press release) - Tue, 09 Feb 2016 06:26



Spero Therapeutics Announces $30 Million Series B Preferred Financing
2, 2016 /PRNewswire/ -- Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced existing Series A investors Atlas Venture, SR One, MRL Ventures, Lundbeckfond Ventures, The Kraft Group ...
PR Newswire (press release) - Tue, 02 Feb 2016 06:26

Spero Eyes First Trial, Gets $30M More to Battle Drug-Resistant Bugs
Xconomy - Tue, 02 Feb 2016 04:56

‚ÄčAtlas startup Spero gets $30M to give new life to old antibiotics
Boston Business Journal (blog) - Tue, 02 Feb 2016 05:18

The Potentiator: Spero Therapeutics gets $30M to up potency of existing ...
MedCity News - Tue, 02 Feb 2016 07:47


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014